Comparable composite endpoints after HLA-matched and HLA-haploidentical transplantation with post-transplantation cyclophosphamide. - Wikidata - awgldk - TriplyDB

Comparable composite endpoints after HLA-matched and HLA-haploidentical transplantation with post-transplantation cyclophosphamide.

Comparable composite endpoints after HLA-matched and HLA-haploidentical transplantation with post-transplantation cyclophosphamide.

http://www.wikidata.org/entity/Q37618838

about

Alternative Donor Graft Sources for Adults with Hematologic Malignancies: A Donor for All Patients in 2017!T Cell-Replete Peripheral Blood Haploidentical Hematopoietic Cell Transplantation with Post-Transplantation Cyclophosphamide Results in Outcomes Similar to Transplantation from Traditionally Matched Donors in Active Disease Acute Myeloid Leukemia.Transplant for NEMO: this and much, much more.Similar outcomes after haploidentical transplantation with post-transplant cyclophosphamide versus HLA-matched transplantation: a meta-analysis of case-control studies.Vorinostat plus tacrolimus/methotrexate to prevent GVHD after myeloablative conditioning, unrelated donor HCT.Toxicological effects of fludarabine and treosulfan conditioning before allogeneic stem-cell transplantation.Better outcome with haploidentical over HLA-matched related donors in patients with Hodgkin's lymphoma undergoing allogeneic haematopoietic cell transplantation-a study by the Francophone Society of Bone Marrow Transplantation and Cellular Therapy.Shortened-Duration Tacrolimus after Nonmyeloablative, HLA-Haploidentical Bone Marrow Transplantation.HSCT for GATA2 deficiency across the pond.

P2860

Q30252339-822F3988-C6D7-4238-AF23-7D00B70A8430 Q39021231-54032028-48D1-4052-BC3C-F5332599DF8E Q41882009-E5360B0D-097F-4385-9E7D-D5F2F264A090 Q42362685-F23D065C-5C8E-4BA3-9574-27A1CB549E07 Q47104749-BD267D80-4E7C-4D6B-ACC8-53D4787DB2D2 Q48165128-BC910DE5-E611-461C-98DF-F1669FAC684C Q48251518-C08C6E95-DACF-4E1A-8CAB-119075BFB072 Q49900727-8C589683-F339-494B-8588-A4E87A4B5DAD Q55005718-751236F7-EA42-4F7A-8C2C-C3689D1917ED

P2860

Comparable composite endpoints after HLA-matched and HLA-haploidentical transplantation with post-transplantation cyclophosphamide.

http://www.wikidata.org/entity/Q37618838

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 20 October 2016

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Comparable composite endpoints ...... nsplantation cyclophosphamide.

@en

Comparable composite endpoints ...... nsplantation cyclophosphamide.

@nl

type

label

Comparable composite endpoints ...... nsplantation cyclophosphamide.

@en

Comparable composite endpoints ...... nsplantation cyclophosphamide.

@nl

prefLabel

Comparable composite endpoints ...... nsplantation cyclophosphamide.

@en

Comparable composite endpoints ...... nsplantation cyclophosphamide.

@nl

P1433

Q37618838-E6D42677-F4F2-4E39-B0CF-8ED450ED1A3F

P1476

Q37618838-5DB5F34A-9A8A-43E5-8741-33D943629FC9

P2093

Q37618838-07D0FB76-C6BF-417A-A2AF-407B54ABAE0C

Q37618838-09BD532F-80A3-4610-AC80-EB45974B9597

Q37618838-0C7828E3-7EA9-4C8C-B9D9-E373179F5311

Q37618838-1006A2BD-A421-4A11-80B6-9173D9743DE6

Q37618838-166CC623-5DED-42BC-A0C8-45B743F2F9F5

Q37618838-20E71D37-1137-423C-8C8A-79963CB9879C

Q37618838-329B2B81-0722-4E6D-BF83-20243A882D5C

Q37618838-38138AB8-F277-4C74-BD1A-972EA6E6188E

Q37618838-3821E3AC-E043-4DD6-9D1B-22EF064F9C14

Q37618838-3AA5F65A-7F69-4373-A2EC-B0CF3BD62ABD

P2860

Q37618838-05D3829D-C48A-4510-A52F-7C3D1D99AED7

Q37618838-06E58733-35D3-4EF0-A596-B0FEBD1ED502

Q37618838-143B713F-3696-4F4A-910B-92C140F50E1F

Q37618838-1D140330-0929-42C3-8E82-0A7D3E8033C9

Q37618838-1FEBDC1B-B3A8-46FA-A48A-87C81D724A2C

Q37618838-309C876B-1FD3-492E-A38A-B92FBBB278E5

Q37618838-349AC481-2AE8-43B8-9498-BE9C5452693A

Q37618838-44EE1F4A-8D35-4768-9278-191D031F3B57

Q37618838-488C59D3-E86F-4C19-B266-A4EBCF08F52B

Q37618838-5CD396F3-85F0-431A-8A32-854ED86A0957

P304

Q37618838-EFC819DB-067C-46F4-B94C-38E488F0DD31

P31

Q37618838-64C4E00B-4C2C-47F1-A365-009B41F29120

P356

Q37618838-A264A375-5B96-4A26-A3B2-6C939CC5C03E

P433

Q37618838-B2733D9B-395E-47E3-88EC-AC9F6D9AF6A4

P478

Q37618838-74EAB19B-9334-4F3B-A30D-4FFC3536E99D

P577

Q37618838-4ED88ADD-D643-4A4A-B88C-7A9F43EF7138

P698

Q37618838-31CC85AE-E9E6-4C4E-81BC-22C3DC1CF67C

P932

Q37618838-A3A70EE8-83DF-4ADD-9E25-6CB1D20AD1E7

P356

HAEMATOL.2016.144139

P1433

P1476

Comparable composite endpoints ...... nsplantation cyclophosphamide.

@en

P2093

Amy E Dezern

http://www.w3.org/2001/XMLSchema#string

B Douglas Smith

http://www.w3.org/2001/XMLSchema#string

Carol Ann Huff

http://www.w3.org/2001/XMLSchema#string

Christopher G Kanakry

http://www.w3.org/2001/XMLSchema#string

Douglas E Gladstone

http://www.w3.org/2001/XMLSchema#string

Ephraim J Fuchs

http://www.w3.org/2001/XMLSchema#string

Gary L Rosner

http://www.w3.org/2001/XMLSchema#string

Heather J Symons

http://www.w3.org/2001/XMLSchema#string

Hua-Ling Tsai

http://www.w3.org/2001/XMLSchema#string

Ivan Borrello

http://www.w3.org/2001/XMLSchema#string

P2860

Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT

Modern approaches to HLA-haploidentical blood or marrow transplantation

Post-transplantation cyclophosphamide for tolerance induction in HLA-haploidentical bone marrow transplantation

Infused total nucleated cell dose is a better predictor of transplant outcomes than CD34+ cell number in reduced-intensity mobilized peripheral blood allogeneic hematopoietic cell transplantation

Increased transplant-related morbidity and mortality in CMV-seropositive patients despite highly effective prevention of CMV disease after allogeneic T-cell-depleted stem cell transplantation.

HLA-haploidentical donor lymphocyte infusions for patients with relapsed hematologic malignancies after related HLA-haploidentical bone marrow transplantation.

Competing risks regression for stratified data.

High-dose cyclophosphamide as single-agent, short-course prophylaxis of graft-versus-host disease.

Patient-reported quality of life is associated with severity of chronic graft-versus-host disease as measured by NIH criteria: report on baseline data from the Chronic GVHD Consortium

Nonmyeloablative HLA-haploidentical bone marrow transplantation with high-dose posttransplantation cyclophosphamide: effect of HLA disparity on outcome

P304

391-400

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3324/HAEMATOL.2016.144139

http://www.w3.org/2001/XMLSchema#string

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

102

http://www.w3.org/2001/XMLSchema#string

P577

2016-10-20T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27846611

http://www.w3.org/2001/XMLSchema#string

P932

5286947

http://www.w3.org/2001/XMLSchema#string